CD4 and cancer: A considerable proportion of clonal 6p LOH is observed in patients with BRCA1/2 alterations, and the functional consequence of 6P LOH in HRD cancers, namely, an increase in dysfunctional CD4+ and CD8+ T cells, is also demonstrated [45].